Dazodalibep
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome
Trial Timeline
Feb 25, 2025 → Dec 11, 2029
NCT ID
NCT06747949About Dazodalibep
Dazodalibep is a phase 3 stage product being developed by Amgen for Sjögren's Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06747949. Target conditions include Sjögren's Syndrome.
What happened to similar drugs?
0 of 7 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06747949 | Phase 3 | Recruiting |
Competing Products
20 competing products in Sjögren's Syndrome